MyFinsight
Home
Blog
About
Proceeds from warrant
inducements
$2,570,274
Disposal of property &
equipment
$1,441
Proceeds from sale of
common stock under atm
$1,522,058
(-54.53%↓ Y/Y)
Net cash provided by
financing activities
$2,311,711
(-28.44%↓ Y/Y)
Net cash provided by
(used in) investing...
$1,441
(144.32%↑ Y/Y)
Canceled cashflow
$1,780,621
Net change in cash
and cash...
$79,998
(101.80%↑ Y/Y)
Canceled cashflow
$2,233,154
something is missing
-$1,366,535
Issuance costs from
warrant inducement
$338,667
Issuance costs for sale of
common stock under atm
$75,419
(-49.39%↓ Y/Y)
Equity-based compensation
$672,102
(-41.12%↓ Y/Y)
Accrued liabilities
$333,641
(183.92%↑ Y/Y)
Accounts payable
$47,104
(107.76%↑ Y/Y)
Prepaid expenses
-$17,966
(-105.68%↓ Y/Y)
Deferred offering costs
-$17,933
(-290.45%↓ Y/Y)
Depreciation expense
$504
(-91.48%↓ Y/Y)
Interest receivable
-$161
(99.16%↑ Y/Y)
Net cash used in
operating activities
-$2,233,154
(70.90%↑ Y/Y)
Canceled cashflow
$1,089,411
Net loss
-$3,322,565
(55.77%↑ Y/Y)
Back
Back
Cash Flow
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)
source: myfinsight.com